IFN-λ4 is associated with increased risk and earlier occurrence of gastrointestinal, respiratory and malarial infections in Malian children
暂无分享,去创建一个
A. Dicko | A. Hutchinson | L. Prokunina-Olsson | P. Albert | Sungduk Kim | O. Onabajo | R. Morrison | M. Fried | P. Duffy | S. Mbulaiteye | Adeola Obajemu | Almahamoudou Mahamar | Oumar Attaher | Michelle Manning | O. Flórez-Vargas | N. Brand | Jennifer L. Kwan | Youssoufa Sidibe | J. Kwan | M. Manning | Youssoufa Sidibé | A. Mahamar
[1] S. Larsson. with at a Mendelian randomization study. , 2020 .
[2] J. Aurelius,et al. IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections , 2019, Front. Cell. Infect. Microbiol..
[3] M. Baldridge,et al. Interactions between noroviruses, the host, and the microbiota. , 2019, Current opinion in virology.
[4] S. Kotenko,et al. Type III IFNs: Beyond antiviral protection. , 2019, Seminars in immunology.
[5] L. Prokunina-Olsson. Genetics of the Human Interferon Lambda Region , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[6] C. Murray,et al. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years , 2018, JAMA pediatrics.
[7] D. Garcin,et al. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission , 2018, eLife.
[8] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[9] J. Goedert,et al. Evaluating the Causal Link Between Malaria Infection and Endemic Burkitt Lymphoma in Northern Uganda: A Mendelian Randomization Study , 2017, EBioMedicine.
[10] S. Kotenko,et al. Interferon‐&lgr; Mediates Non‐redundant Front‐Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness , 2017, Immunity.
[11] H. Virgin,et al. Expression of Ifnlr1 on Intestinal Epithelial Cells Is Critical to the Antiviral Effects of Interferon Lambda against Norovirus and Reovirus , 2017, Journal of Virology.
[12] Chad A Shaw,et al. A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection , 2017, Proceedings of the National Academy of Sciences.
[13] Jamie Perin,et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals , 2016, The Lancet.
[14] D. Graham,et al. Replication of human noroviruses in stem cell–derived human enteroids , 2016, Science.
[15] S. Beinke,et al. IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment , 2016, EMBO molecular medicine.
[16] S. Smirnov,et al. Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections , 2016, PLoS pathogens.
[17] L. Prokunina-Olsson,et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. , 2015, Journal of hepatology.
[18] Michael S. Diamond,et al. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond , 2015, Immunity.
[19] R. Hartmann,et al. Guarding the frontiers: the biology of type III interferons , 2015, Nature Immunology.
[20] J. Renauld,et al. Interferon-λ and interleukin-22 cooperate for the induction of interferon-stimulated genes and control of rotavirus infection , 2015, Nature Immunology.
[21] M. Diamond,et al. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection , 2015, Science.
[22] Maxim N. Artyomov,et al. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity , 2015, Science.
[23] T. Bergström,et al. Diarrhoeagenic microbes by real-time PCR in Rwandan children under 5 years of age with acute gastroenteritis. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[24] M. Dennis,et al. Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4) , 2014, PLoS genetics.
[25] Marion Koopmans,et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. , 2014, The Lancet. Infectious diseases.
[26] M. Carrington,et al. IFNL 3 ( IL 28 B ) favorable genotype escapes hepatitis C virus-induced microRNAs and mRNA decay , 2013 .
[27] Barbara Rehermann,et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.
[28] H. Tsutsumi,et al. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. , 2011, Virus research.
[29] M. Hornef,et al. IFN-λ determines the intestinal epithelial antiviral host defense , 2011, Proceedings of the National Academy of Sciences.
[30] David B. Goldstein,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.
[31] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[32] Thomas Berg,et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.
[33] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[34] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[35] C. Dye,et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. , 2002, The Lancet. Infectious diseases.